Top Page
Mayne Pharma Group
(Sydney:MYX)
Mayne Pharma Group (MYX) vs. iShares MSCI Australia ETF (EWA)
Mayne Pharma Group Business Overview & Revenue Model
Mayne Pharma Group Earnings Call Summary
Mayne Pharma Group Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 407.11M | 408.10M | 388.15M | 183.59M | 157.15M | 400.78M |
| Gross Profit | 223.22M | 247.27M | 218.53M | 26.84M | 23.75M | 127.02M |
| EBITDA | 23.38M | 42.08M | -116.93M | -193.80M | -78.88M | -182.40M |
| Net Income | -83.23M | -93.84M | -174.23M | 117.25M | -281.29M | -208.42M |
Balance Sheet | ||||||
| Total Assets | 940.55M | 1.01B | 1.14B | 1.25B | 1.30B | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 67.35M | 100.40M | 149.28M | 220.14M | 97.08M | 98.35M |
| Total Debt | 44.62M | 41.27M | 38.82M | 47.51M | 413.67M | 346.82M |
| Total Liabilities | 587.84M | 644.32M | 688.99M | 613.77M | 764.89M | 706.56M |
| Stockholders Equity | 352.71M | 370.28M | 454.19M | 634.36M | 545.88M | 768.36M |
Cash Flow | ||||||
| Free Cash Flow | 15.72M | 5.19M | -36.16M | -262.71M | -28.47M | 22.16M |
| Operating Cash Flow | 22.43M | 17.47M | -15.30M | -43.12M | -16.62M | 47.26M |
| Investing Cash Flow | -4.90M | -68.07M | 53.45M | 473.49M | -28.53M | -49.25M |
| Financing Cash Flow | -3.50M | -556.00K | -19.85M | -431.48M | 27.60M | -28.83M |
Mayne Pharma Group Technical Analysis
Mayne Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$367.13M | 13.97 | 22.84% | 0.88% | 21.47% | 89.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$545.28M | -3.40 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$246.16M | -5.17 | -83.97% | ― | 1271.12% | 36.87% | |
47 Neutral | AU$1.27B | -5.54 | -54.37% | ― | ― | -29.93% | |
44 Neutral | AU$97.09M | -6.27 | -31.98% | ― | 34.20% | -23.90% | |
43 Neutral | AU$194.18M | -4.23 | -21.13% | ― | 5.07% | 46.14% |
Mayne Pharma Group Corporate Events
Mayne Pharma Group has announced a proposed issue of up to 161,725 performance rights, designated under the ASX security code MYXAN. The securities are to be issued as part of a placement or other type of issue, with a proposed issue date of 31 March 2026, signaling an equity-based component likely tied to staff or executive incentives and potentially modest dilution for existing shareholders.
The move reflects the company’s continued use of performance-linked equity instruments within its capital management and remuneration framework. While the scale of the issue is relatively limited, it underscores Mayne Pharma’s focus on aligning management incentives with shareholder value and maintaining flexibility in its capital structure as it executes its strategic and operational plans.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has announced that director Shawn Patrick O’Brien has ceased to be a director of the company as of 20 February 2026 (U.S. time). The final director’s interest notice lodged with the ASX details O’Brien’s remaining holdings in Mayne Pharma, including performance rights and ordinary shares held directly and through a custodian under the company’s performance rights and option plan, providing transparency for investors on his equity position at the time of departure.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has released its first-half fiscal 2026 results presentation, highlighting the use of both IFRS and non-IFRS metrics, including EBITDA, to illustrate underlying operating performance. The company positions EBITDA as a key measure for investors to assess the business, while noting that certain non-IFRS figures are unaudited and adjusted for specified income and expenses.
The release also underscores the uncertainty surrounding forward-looking statements, stressing that a range of external factors, from regulatory changes to supply chain disruptions, could materially affect future outcomes. By emphasising disclosure practices and clarifying the status of its trademarks and product portfolio, Mayne Pharma aims to frame investor expectations and reinforce transparency around how it communicates financial and operational performance.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma reported first-half FY26 revenue of A$212.1 million, broadly flat year on year, but lifted group gross margin to 65.3% through disciplined pricing, mix and channel execution. Underlying EBITDA slipped 8% to A$28.6 million and adjusted operating cash flow from continuing operations fell 41% to A$16.9 million, with management citing scheme-related legal costs and earn-out payments, while reaffirming a focus on balancing investment, cost control and capital management, including potential buybacks and acquisitions.
Women’s Health revenue rose 2% to A$96.5 million, driven by rising prescription volumes across its key brands, although higher sales investment trimmed direct contribution by 8%, as the company seeks to build scale and leverage expected tailwinds from regulatory shifts in hormone replacement therapies. The dermatology unit delivered a 35% increase in direct contribution to A$29.8 million despite a modest revenue decline, as new product launches, mix benefits and the expansion of its direct-to-patient channel reinforced the strategic value of its disintermediation model and set up further growth into adjacent therapeutic areas.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Vanguard Group, through The Vanguard Group, Inc. and its controlled entities including Vanguard Investments Australia Ltd., has notified Mayne Pharma Group Limited that it has ceased to be a substantial holder in the company. As of 2 February 2026, Vanguard’s voting power in Mayne Pharma stands at 4.972%, down from a previously higher level that met Australia’s substantial holding threshold, indicating a reduction in its shareholding but continued, albeit smaller, institutional investment presence in the stock.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited reported that all resolutions put to shareholders at its 29 January 2026 Annual General Meeting were approved, including the re-election of directors Ann Custin and David Petrie, adoption of the remuneration report, and the issue of long-term incentive performance rights to the CEO and managing director under the company’s employee equity plan. The strong level of support across the resolutions, despite a notable minority vote against the remuneration report and incentive grant, signals continued shareholder backing for the current board composition and executive incentive structures, reinforcing management’s mandate as the company executes its strategic and operational plans in a competitive pharmaceuticals market.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has convened its 2025 Annual General Meeting in Melbourne on 29 January 2026, following an extension granted by the corporate regulator due to delays in completing its proposed Scheme of Arrangement with Cosette Pharmaceuticals. The Chair, Professor Bruce Robinson, formally opened the hybrid AGM, outlined participation and voting procedures for both in-person and online shareholders, and introduced the board, senior executives and auditor, underscoring the company’s ongoing governance processes despite the setback in finalising the Cosette transaction.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Goldman Sachs Group, including its Australian subsidiaries, has notified Mayne Pharma Group that it has ceased to be a substantial shareholder in the company as of 15 January 2026, in line with disclosure requirements under the Corporations Act. The change in holding, formally lodged with the ASX via a substantial shareholder notice, signals that Goldman Sachs’ aggregate voting interest in Mayne Pharma has fallen below the substantial shareholder threshold, potentially altering the company’s institutional investor base and the balance of influence among its major shareholders.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has received a formal notice of appeal from Cosette Pharmaceuticals and its BidCo lodged with the New South Wales Court of Appeal, challenging a prior Supreme Court judgment that had found in favour of Mayne Pharma. The appeal targets the court’s findings on Mayne Pharma’s FY25 EBITDA, which was central to Cosette’s misleading and deceptive conduct claim, and on Cosette’s allegation that a material adverse change had occurred based on Q3 FY25 sales metrics; Mayne Pharma has indicated it is reviewing the appeal and intends to vigorously defend the earlier ruling, signalling a continued legal overhang that could influence perceptions of the company’s financial performance and deal-related risk among investors and other stakeholders.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has announced that director Frank Charles Condella Jr has ceased to be a director of the company effective 14 January 2026. At the time of his departure, Condella held 65,929 ordinary shares in Mayne Pharma, and the company reported no additional indirect security holdings or contractual interests linked to his role, indicating a straightforward change in board composition without disclosed related-party or contractual complexities.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has announced a streamlining of its board, with long-serving chair Frank Condella retiring effective 14 January 2026 and non-executive directors Patrick Blake and Anne Lockwood set to step down following the release of the company’s half-year results in February 2026. Professor Bruce Robinson, a non-executive director since 2014 with extensive governance and healthcare sector experience, has been appointed non-executive chair, while the board continues to review its composition to ensure it has the skills and expertise needed to drive shareholder value; the company has also recommended shareholders support the re-election of directors Ann Custin and David Petrie at the upcoming annual general meeting.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has issued 1,090,360 unquoted performance rights under its employee incentive scheme, effective 30 December 2025. The new equity-based awards, which are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, underscore the company’s ongoing use of long-term incentives to align employee and executive interests with shareholder value and support retention in a competitive pharmaceutical talent market.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has notified the market of the issue of 25,592 new ordinary fully paid shares following the conversion or exercise of previously unquoted equity securities, effective 31 December 2025. The modest increase in issued capital reflects the crystallisation of existing equity incentives or convertible instruments, marginally diluting existing shareholders while signalling ongoing utilisation of equity-based funding and remuneration typical for companies in the pharmaceutical sector.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has notified the market that 100,543 performance rights have lapsed after the conditions attached to those rights were not satisfied by the 30 December 2025 deadline. The cessation of these securities reduces the company’s potential future share issuance under its incentive arrangements and may slightly lessen prospective dilution for existing shareholders, while also indicating that certain performance hurdles or targets tied to management or employee incentives were not met.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has disclosed changes in the holdings of director Shawn Patrick O’Brien, reflecting the exercise of performance rights and restricted stock unit (RSU) performance rights under the company’s Performance Rights and Option Plan. Between 16 and 18 December 2025, O’Brien exercised a substantial number of performance rights, resulting in the acquisition of 326,452 ordinary shares and the disposal of 35,170 RSU performance rights and 364,103 performance rights, some through exercise and others forfeited for not meeting vesting conditions, with a portion of the resulting shares sold on-market to cover tax obligations. Following these transactions, O’Brien now holds 568,193 performance rights and 37,041 ordinary shares directly, and 220,532 ordinary shares indirectly through the plan custodian, signalling a shift from derivative-style incentives into a larger direct and indirect equity stake in the company.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has notified the market that 241,192 performance rights (ASX code: MYXAN) have lapsed after the conditions attached to these conditional rights were not met or became incapable of being satisfied as of 16 December 2025. The cessation of these securities effectively reduces the company’s potential future share dilution under its incentive arrangements and may signal that certain performance or vesting hurdles tied to these rights were not achieved, which could be relevant for investors tracking executive or employee equity incentives and capital structure dynamics.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has issued 1,356,532 new fully paid ordinary shares following the exercise or conversion of previously unquoted options or other convertible securities, with an effective issue date of 22 December 2025. The move modestly increases the company’s share capital base and reflects the crystallisation of equity-based incentives or financing instruments, which may slightly dilute existing shareholders while signalling ongoing engagement of option and convertible security holders with the company’s equity.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has confirmed details for its 2025 Annual General Meeting, which will be held in hybrid format at a Melbourne venue and online on 29 January 2026, following an extension of time granted by the corporate regulator. Shareholders will be asked to consider the company’s statutory reports for the year ended 30 June 2025, vote on the re-election of directors, adopt the 2025 remuneration report and approve a long-term incentive grant of performance rights to the CEO and managing director, with the meeting positioned as a key forum for engagement on management, governance and executive pay.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma reported a mixed unaudited trading update for the first five months of FY26, with group net revenue down 5.5% to $165 million and underlying EBITDA roughly halved to $11.5 million amid higher marketing spend, FDA post-approval study costs and pricing pressure in parts of its dermatology portfolio. While total direct contribution slipped 7.3% to $49.7 million, the company highlighted strong prescription and volume growth across its women’s health franchise, improved gross margins in dermatology driven by TWYNEO and EPSOLAY, and stronger international gross margins, underpinned by Australia’s PBS listing for NEXTSTELLIS, expected US regulatory tailwinds for BIJUVA and IMVEXXY, and ongoing investment in sales, marketing and domestic manufacturing as the board reviews strategic options to maximise long-term shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has officially opened its expanded manufacturing facility in Salisbury, South Australia, which has been modernized with an $18 million investment. The facility, supported by a $4.8 million government grant, enhances production efficiency and capacity, positioning the company for new product launches and exports, and contributing to a 7% revenue increase in FY25.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has terminated its Scheme Implementation Deed (SID) with Cosette due to material breaches by Cosette, which Mayne Pharma deemed willful and intentional. This termination releases Mayne Pharma from the restrictions of the SID and does not obligate them to pay a break fee. The company is considering further actions regarding Cosette’s breaches and has notified Cosette of its intention to enforce a costs order made against them. Mayne Pharma will keep its shareholders informed of any further developments related to this termination.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has received a notice from Cosette Pharmaceuticals purporting to terminate their Scheme Implementation Deed (SID) due to unmet conditions. However, Mayne Pharma disputes the validity of this termination, arguing that Cosette’s failure to meet its obligations under the SID contributed to the unmet conditions. The company has reserved its rights regarding Cosette’s non-compliance, potentially impacting the future of their collaboration and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has issued a notice of intention to terminate the Scheme Implementation Deed with Cosette Pharmaceuticals due to material breaches by Cosette. These breaches include failing to meet obligations related to FIRB approval and debt financing, which could impact the proposed acquisition. Mayne Pharma reserves the right to terminate the agreement if the breaches are not resolved within five business days, potentially affecting its strategic plans and stakeholder interests.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$3.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.